Key result
Higher HbA1c is linked to ~99% greater risk of cardiometabolic multimorbidity per 1% increase.
Why the study?
The comparative associations and predictive utility of glycated hemoglobin and fasting plasma glucose for cardiometabolic multiple long-term conditions risk were unclear.
Are higher levels of HbA1c and FPG associated with an increased risk of incident cardiometabolic multiple long-term conditions in older adults?
Cohort (n=2,233)
Are higher levels of HbA1c and FPG associated with an increased risk of incident cardiometabolic multiple long-term conditions in older adults?
Answers are grounded in this paper and cite their sources.
In older adults, HbA1c is a substantially stronger and more informative marker than fasting plasma glucose for predicting the risk of developing cardiometabolic multiple long-term conditions.
Objective To examine and contrast the associations of glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) with the risk of cardiometabolic multiple long-term conditions (cMLTC) and evaluate their incremental predictive utility. Patients and Methods The study analyzed 2233 adults (mean age 63; 1009 (45.2%) men) free of hypertension, coronary disease, diabetes, and stroke at baseline (wave 4; 2008-2009). Incident cardiometabolic multimorbidity (≥2 of these conditions) was assessed at wave 10 (2021-2023). Logistic regression, restricted cubic splines, and discrimination metrics evaluated predictors and predictive performance. Results Over 12-15 years, 129 participants developed cMLTC (57.8 per 1000; 95% CI, 48.5-68.3). Restricted cubic splines showed continuous, dose–response relationships between HbA1c and FPG with cMLTC risk. HbA1c was strongly associated with cMLTC (per 1% increase, OR 1.99; 95% CI, 1.51-2.63; highest vs lowest tertile, OR 3.15; 95% CI, 2.00-4.94), whereas FPG associations were more modest (per 1 mmol/L: OR 1.39; 95% CI, 1.18-1.64; tertile: OR 1.98; 95% CI, 1.23-3.19) and attenuated after mutual adjustment. Adding HbA1c to established risk factors improved discrimination (ΔC-index=0.0344, P <.001) and fit ( P <.001) more than FPG (ΔC-index=0.0171, P =.017; between-marker P =.050). Conclusion In this nationally representative cohort of older adults in England, higher HbA1c and FPG levels were each associated with an increased risk of cMLTC and enhanced risk prediction. However, HbA1c emerged as a substantially stronger and more informative marker than FPG.
No takes yet. Share an insight, caveat, or question.
Seidu et al. (2026) conducted a cohort in Cardiometabolic multiple long-term conditions (cMLTC) (n=2,233). Glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) vs. Lower levels (e.g., lowest tertile) was evaluated on Incident cardiometabolic multimorbidity (≥2 of these conditions) (OR 1.99, 95% CI 1.51-2.63). Higher HbA1c was strongly associated with incident cardiometabolic multimorbidity (OR 1.99 per 1% increase; 95% CI 1.51-2.63), serving as a stronger predictive marker than fasting plasma glucose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: